RxDoctor Payments Data

Vernon Orton, MD

Urology · Richmond, VANPI 1083823009

Payments from drug & device makers

$7,339in general payments, 2019–2025

Across 303 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$743
  • Blue Earth Diagnostics$665
  • Bayer$603
  • Johnson & Johnson$565
  • Astellas Pharma US Inc$531
  • Pfizer$379
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,11497%
  • Education$2253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,339 in reported general payments places this provider in the 65th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$301,615
Medicare patients
943
Services billed
23,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide47$650,714
ErleadaApalutamide13$181,872
OrgovyxRelugolix13$34,366
MyrbetriqMirabegron36$31,965
Tolterodine Tartrate ErTolterodine Tartrate42$4,826
Tamsulosin Hcl266$2,999
Finasteride132$1,613
CefuroximeCefuroxime Axetil51$855
Oxybutynin Chloride ErOxybutynin Chloride18$746
Solifenacin Succinate19$541
Oxybutynin Chloride28$465
Alfuzosin Hcl ErAlfuzosin Hcl23$455
Dutasteride19$383
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$344
Ciprofloxacin Hcl85$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$531$682,67983 claims
Johnson & JohnsonErleada$565$181,87213 claims
Sumitomo Pharma America, Inc.Orgovyx$239$34,36613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 300 urology providers in Virginia.

Other urology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →